Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

F45 Training Holdings Inc., a leading global fitness community known for innovative, high-energy group workouts, announced ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...

Highmark Health President and CEO David Holmberg discussed the uncertainties facing the insurance industry, including the ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.